FDA Clearance Tracker · P210007
Vivistim® System
Last checked: Nov 20, 2026Latest source record: Aug 27, 2021 (this decision)Source: openFDAMethods & limitations
Decided
Aug 27, 2021
Approved
Time to decision
178 days
Received Mar 2, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P210007
- Device name
- Vivistim® System
- Applicant
- Mobia Medical, Inc.
- Applicant location
- Austin, TX
- Received
- Mar 2, 2021
- Decided
- Aug 27, 2021
- Decision
- Approved
- Supplements
- 14 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval the MicroTransponder® Vivistim® Paired VNS System (Vivistim ® System) is intended to be used to stimulate the vagus nerve during rehabilitation therapy in order to reduce upper extremity motor deficits and improve motor function in chronic ischemic stroke patients with moderate to severe arm impairment.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code QPY (Stimulator, autonomic nerve, implanted for stroke rehabilitation).
- It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).
Source documents
Other decisions for Mobia Medical, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.